New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
16:10 EDTAERIAerie Pharmaceuticals reports Q4 GAAP EPS (62c), consensus (25c)
Included in the $10.3M net loss and the (62c) EPS are non-cash charges totaling $4.9M, of which $1.3M represents stock-based compensation expense included in operating expenses. With these non-cash items excluded, the adjusted operating expenses of $5.4M include adjusted research and development expenses of $3.0M and adjusted general and administrative expenses of $2.4M. In addition to the $1.3M stock-based compensation expense, the $4.9M in non-cash charges include a $2.7M extinguishment loss related to the conversion of the Company’s outstanding convertible promissory notes to common equity upon the closing of the IPO and $900,000 in accrued interest and amortization expense related to the Company’s notes that were converted to common equity upon the closing of the IPO.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
14:18 EDTAERIAerie accelerated data read-out a positive, says Cantor
Subscribe for More Information
06:31 EDTAERIAerie Pharma accelerates of timeline for reporting results from Rhopressa trial
Aerie Pharmaceuticals announced the acceleration of the expected timeline for reporting efficacy results from the company’s 400-patient Phase 3 registration trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of RhopressaTM compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named “Rocket 3.” Pending the continued advancement of the RhopressaTM Phase 3 program and regulatory approvals, Aerie intends to commercialize RhopressaTM in North American markets and possibly Europe with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use